Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up

Contributed by: Business Wire

Logo

Images

The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire)

The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire)

The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire)

Business Wire embedded0

Tags

Health

Medical Devices

Other Health

Clinical Trials

Research

Science

Biotechnology

ReActiv8

More Like This

Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®

Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients

Mainstay Medical Announces US$125 Million Equity Financing Transaction

Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM

Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM

Mainstay Medical Announces New ICD-10 Diagnosis Code for Multifidus Dysfunction

PR Newswire associated0

San Raffaele Hospital (Milan, Italy): new, promising results from the first patients implanted with the spinal neurostimulator. A new, high-frequency spinal stimulation protocol gives hope for motor recovery and reduced muscular spasticity

ONWARD® Medical Announces Publication Highlighting Evidence-based Programming for ARC-EX® Therapy